1320 ET - MBX Biosciences is off 5.5% following results of a Phase 2 trial of its canvuparatide treatment for hypoparathyroidism. Mizuho says the drug achieved a 57% composite responder rate, a metric for treatment success, at 52 weeks, which is comparable to its competitor Yorvipath's 64%. That said, the analysts believe some investors might argue that Yorvipath's real benchmark rate is 80% under a more relaxed standard tied to patient use. But the analysts are still upbeat on the results and canvuparatide's once-weekly dosing schedule, which allows for 86% fewer injections and "continue to support canvuparatide's commercial potential," they say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
June 12, 2026 13:21 ET (17:21 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.